10 unknown, 7 completed, 2 active not recruiting, 1 recruiting. 9 Phase 4, 5 Phase 2, 2 Phase 3, 1 Not applicable, 1 Phase 1.
Follow Nucleosides: new trials by email Literature Review of Nucleosides trials Research Report on Nucleosides
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection Placebo, TQA3334 Tablet, Nucleoside (acid) analogs (NAs) - Chronic Hepatitis B | Phase 2 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 116 | 2024-12-04 | 2026-09-11 |
| Development and Validation of Models to Predict Functional Cure in Patients With CHB After Peg-IFN Based Therapy Peginterferon-α; Nucleoside analogs - Hepatitis B, Chronic | Unknown | Qilu Hospital of Shandong University | 1000 | 2024-01-06 | 2024-02-07 | |
| A Retrospective Observational Study on the Effects of Probiotics on HBsAg Clearance PegIFNα2b, PegIFNα2b+probiotics, Nucleoside analog - Chronic Hepatitis B | Unknown | Qilu Hospital of Shandong University | 40 | 2023-05-09 | 2024-05-01 | |
| A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia Nucleoside/nucleotide reverse transcriptase inhibitors (NrtIs), HH-003 and NrtIs, HH-003, NrtIs and PEG-IFN-α - Chronic HBV Infection | Phase 2 | Completed | Huahui Health | 74 | 2022-07-20 | 2024-10-15 |
| Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients Peginterferon Alfa-2B, Nucleoside Analogs - Hepatitis B, Chronic | Phase 4 | Recruiting | Third Affiliated Hospital, Sun Yat-Sen University | 5000 | 2022-01-08 | 2025-05-01 |
| Stopping Antiviral Treatment in Chronic Hepatitis B Entecavir - Chronic Hepatitis b | Active not recruiting | The University of Hong Kong | 54 | 2021-06-01 | 2026-02-10 | |
| Inflammation and Co-Infections in D²EFT NRTIs, Darunavir, Ritonavir - HIV-infection/Aids, Human Herpesvirus 4 Infections | Phase 4 | Withdrawn | Kirby Institute | 2021-02-01 | 2020-11-10 | |
| A Cohort Study on Long-term Clinical Outcomes of Antiviral Therapy in Patients With Chronic Hepatitis B and Cirrhosis interferon - Chronic Hepatitis b | Unknown | Beijing Ditan Hospital | 10000 | 2020-04-01 | 2020-03-10 | |
| Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibody, Nucleoside/nucleotide analogues - Hepatitis B, Chronic | Phase 2 | Unknown | Henlix, Inc | 44 | 2019-12-31 | 2020-10-20 |
| Body Composition Sub-study of the D2EFT Trial Darunavir (DRV) 800 milligram (MG) Oral Tablet, Ritonavir 100 MG Oral Tablet, N(t)RTIs - HIV Infections | Phase 4 | Completed | Kirby Institute | 155 | 2019-12-05 | 2025-01-09 |
| Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor Inarigivir soproxil, Nucleoside/nucleotide (NUC) analogue inhibitors - Hepatitis B, HBV | Phase 2 | Terminated | F-star Therapeutics, Inc. | 64 | 2019-06-18 | 2020-07-22 |
| The Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAg Peginterferon Alfa, Nucleoside Analog (Substance) - Chronic Hepatitis B | Phase 4 | Unknown | Third Affiliated Hospital, Sun Yat-Sen University | 200 | 2019-01-01 | 2019-01-15 |
| Dolutegravir and Darunavir Evaluation in Adults Failing Therapy NRTIs, Dolutegravir, Darunavir - HIV Infections | Phase 4 | Unknown | Kirby Institute | 831 | 2017-11-23 | 2023-04-18 |
| To Study the Effect of Adding on Pegylated Interferon (PEG-INF) Therapy for Patients Diagnosed With Chronic Hepatitis B PEG-IFN & Nucleos(t)tide analogues, Nucleos(t)tide analogues - Hepatitis B | Phase 4 | Unknown | King Abdullah International Medical Research Center | 214 | 2015-03-01 | 2018-03-09 |
| Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection curative resection, thymalfasin, nucleoside analog (suggest to use entecavir) - Curable Hepatitis B Virus-Related Hepatocellular Carcinoma | Phase 4 | Unknown | Jia Fan | 360 | 2015-01-01 | 2014-11-21 |
| HBsAg Decline After Pegylated-interferon-α in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance PEG-interferon-Alfa-2A, Nucleosides - Chronic Hepatitis B | Phase 3 | Unknown | Pusan National University Hospital | 144 | 2013-05-01 | 2014-11-04 |
| Cryptococcal Optimal ART Timing Trial efavirenz, nucleoside - Cryptococcal Meningitis, HIV Infections | Phase 4 | Completed | University of Minnesota | 177 | 2010-11-01 | 2020-06-09 |
| A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen raltegravir, 2N(t)RTI, Ritonavir-boosted lopinavir - HIV Infections | Phase 4 | Completed | Kirby Institute | 558 | 2009-09-01 | 2026-03-27 |
| A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer ARRY-334543, EGFR/ErbB2 inhibitor; oral, Gemcitabine, nucleoside analogue; intravenous - Advanced Cancer, Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Array BioPharma | 20 | 2009-03-01 | 2012-10-04 |
| Early Response to Interferon Combined Short-Term Nucleoside Analogue Therapy in HBeAg(+) Chronic Hepatitis B interferon α plus nucleoside analogue, interferon α - Hepatitis B, Chronic | Not applicable | Unknown | Sun Yat-sen University | 50 | 2008-01-01 | 2009-03-12 |
Showing 20 of 22. Sign in to see all of them.
Hepatitis B, Chronic (12) · HIV Infections (5) · Acquired Immunodeficiency Syndrome (3) · Hepatitis B (3) · Carcinoma, Hepatocellular (1) · Coinfection (1) · Cryptococcosis (1) · Cytomegalovirus Infections (1) · Epstein-Barr Virus Infections (1) · Fatty Liver (1) · Heartburn (1) · Inflammation (1) · Meningitis, Cryptococcal (1) · Opportunistic Infections (1) · Pancreatic Neoplasms (1)
Kirby Institute (4) · Qilu Hospital of Shandong University (2) · Third Affiliated Hospital, Sun Yat-Sen University (2) · Array BioPharma (1) · Beijing Ditan Hospital (1) · Bristol-Myers Squibb (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · F-star Therapeutics, Inc. (1) · Henlix, Inc (1) · Huahui Health (1) · Jia Fan (1) · King Abdullah International Medical Research Center (1) · Mahidol University (1) · Pusan National University Hospital (1) · Sun Yat-sen University (1)
China (9) · South Africa (4) · India (3) · Malaysia (3) · Thailand (3) · Argentina (2) · Chile (2) · Hong Kong (2) · Mexico (2) · Nigeria (2) · Taiwan (2) · United Kingdom (2) · United States (2) · Zimbabwe (2) · Australia (1)
Abduljaleel Alalwan, MD (1) · Baoshan Yang (1) · Bigang Xiong (1) · Bihua Gao (1) · Bihui Zhong (1) · Bin Liu (1) · Bin Zhou (1) · Binhong Fu (1) · Brian Gazzard, MD (1) · Caihua Jiang (1) · Changxia Niu (1) · Changzheng Hu (1) · Cheng-Yuan Peng, MD, PhD (1) · Chengfang Zheng (1)
PMID 23769235, PMID 24204757, PMID 24963568, PMID 25723472, PMID 26094695, PMID 26632544, PMID 30325463, PMID 31319498, PMID 31504335, PMID 32843994, PMID 33399309, PMID 35867702, PMID 38721980, PMID 38788744, PMID 39972326, PMID 40390028, PMID 41229921, PMID 41779383, PMID 42350969
U01AI089244 (1)